EP1406669A2 - Conjugues d'antioxydants et de ligands de chelation metallique - Google Patents

Conjugues d'antioxydants et de ligands de chelation metallique

Info

Publication number
EP1406669A2
EP1406669A2 EP01987230A EP01987230A EP1406669A2 EP 1406669 A2 EP1406669 A2 EP 1406669A2 EP 01987230 A EP01987230 A EP 01987230A EP 01987230 A EP01987230 A EP 01987230A EP 1406669 A2 EP1406669 A2 EP 1406669A2
Authority
EP
European Patent Office
Prior art keywords
compound
produce
iii
stracture
contacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01987230A
Other languages
German (de)
English (en)
Inventor
Ramachandra S. Ranganathan
Helen Fan
Michael F. Tweedle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco International BV
Original Assignee
Bracco International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco International BV filed Critical Bracco International BV
Publication of EP1406669A2 publication Critical patent/EP1406669A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0419—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Definitions

  • the present invention relates to diagnostic and therapeutic compositions, methods of their use, and processes of their preparation.
  • vitamin C vitamin C
  • 2-O-octadecylascorbic acid an ascorbic acid derivative with antioxidant properties, 2-O-octadecylascorbic acid, has been prepared and has been shown to markedly inhibit the myocardial lesions induced by ischemia- reperfusion treatment in rats.
  • Ascorbic acid may also bind to the human serum albumin (HS A) weakly with a binding constant of about 3.5 x 10 4 M "1 .
  • Ascorbic acid and other antioxidants have been used to stabilize radiopharmaceuticals by decreasing the oxidation of substituents due to radical reactions induced by the decay of the radionuclide.
  • Metal chelating ligands are designed for use in Nuclear Medicine, Magnetic Resonance Imaging (MRI), and neutron capture therapy applications.
  • Magnetic resonance (hereinafter sometimes referred to as MR) imaging is widely used for obtaining spatial images of parts of a patient for clinical diagnosis.
  • the image is obtained by placing the patient in a strong external magnetic field and observing the effect of this field on the magnetic properties of protons contained in and surrounding the organ or tissue of the patient.
  • the proton relaxation times, called Ti or spin-lattice or longitudinal relaxation time, and T 2 or spin-spin'or transverse relaxation time depend on the chemical and physical environment of the organ or tissue being imaged.
  • a diagnostic agent is administered intravenously (hereinafter sometimes referred to as IV.) and is taken up by the organs, such as the liver, spleen, and lymph nodes to enhance the contrast between healthy and diseased tissues.
  • contrast agents used in MR imaging derive their signal-enhancing effect from the inclusion of a material exhibiting paramagnetic, ferrimagnetic, ferromagnetic or superparamagnetic behavior. These materials affect the characteristic relaxation times of the imaging nuclei in the body regions into which they distribute causing an increase or decrease in MR signal intensity.
  • contrast agents such as those of the present invention, that selectively enhance signal intensity in particular tissue types, as most MR contrast agents are relatively non-specific in their distribution.
  • Nuclear medicine procedures and treatments are based on internally distributed radioactive materials, such as radiopharmaceuticals or radionuclides, which emit electromagnetic radiations as alpha or beta particles or as gamma rays or photons.
  • radioactive materials such as radiopharmaceuticals or radionuclides, which emit electromagnetic radiations as alpha or beta particles or as gamma rays or photons.
  • gamma rays are readily detected and quantified within the body using instrumentation such as scintillation and gamma cameras.
  • Compounds derivatized with alpha or beta emitters may be used for radiotherapeutic applications, providing an internal dose of cytotoxic radiation at their target tissues(s).
  • the invention relates to conjugates of an antioxidant and one or more metal chelating ligands that may be chelated to radioactive or non-radioactive metals and use of such conjugates chelated to such metals as, for example: a) Magnetic resonance diagnostic compositions for visualization of tissues and compartments that bind or utilize an antioxidant conjugated to metal chelates; b) Radiodiagnostic compositions for visualization of tissues, comprising ligands chelated to radioactive gamma-emitting metals and coupled to said antioxidant conjugates; and c) Compositions for radiotherapy or for neutron capture therapy, comprising ligands chelated to radioactive alpha or beta-emitting metals or to metals suitable for neutron capture therapy and coupled to said antioxidant conjugates.
  • the invention provides novel conjugates of antioxidants and metal chelating ligands.
  • the invention also provides novel intermediates, methods of making the conjugates and intermediates, methods of stabilizing radiopharmaceutical ligands, and kits for preparing radiopharmaceuticals.
  • Antioxidants which may be used in the present invention include ascorbic acid, » ⁇ r -aminobenzoic acid (PABA), cysteine, monothioglycerol, and gentisic acid. Ascorbic acid is a preferred antioxidant of the invention.
  • the invention provides a compound having the following chemical structure:
  • M is 9 y 9 y m m Tpccountry 6 Ho, 165 Dy, 64 Cu, 67 Cu, 97 Ru, 103 Ru. °Re, 100 Re, 3 Pb, Bi, 21 l 2Bi, 21 l 3 J ⁇ Bi, 21 l 4 ⁇ Bi,
  • X is CH 2 , an amino acid, a peptide, a protein, or an antibody.
  • X is CH 2 .
  • X is the amino acid represented by the chemical structure:
  • the metal (M) is 99m Tc, 186 Re, 188 Re, 90 Y, 88 Y, 86 Y, 177 Lu, or gadolinium (III).
  • kits for preparing a radiopharmaceutical include an oxidant covalenffy bound to a complexing (or radiopharmaceutical ligand).
  • the kit includes a targeting molecule bound to the antioxidant, the ligand, or, most preferably, both, hi certain of these embodiments, the targeting molecule is an amino acid, a peptide, a protein, or an antibody.
  • the invention provides methods of stabilizing a radiopharmaceutical ligand, which optionally includes a targeting molecule, by conjugating the radiopharmaceutical ligand with an antioxidant.
  • DESCRIPTION OF THE INVENTION The following abbreviations are used in this specification: "DOTA” means 1 ,4,7, 10-tetraazacyclododecane- 1 ,4,7, 10-tetraacetic acid; "HATU” means
  • DLEA means diisopropylethylamine
  • DMF means N,N-dimethylformamide
  • TsCl means p-toluenesulfbnyl chloride
  • THF means tetrahydrofuran
  • TFA trifluoroacetic acid
  • RT room temperature
  • radiopharmaceutical ligand are used interchangeably throughout this specification, except where the context requires otherwise.
  • the present invention is directed, in part, to conjugates of an antioxidant, such as ascorbic acid, and one or more polydentate macrocyclic or non- macrocyclic metal-chelating ligand residues that are optionally chelated to radioactive or non-radioactive metals capable of either being detected by imaging means for diagnosis or capable of providing a therapeutic or radiotherapeutic effect.
  • the metal chelating groups can be either macrocyclic or non-macrocyclic multidentate metal chelating ligands, and the structure of these ligands and the metals that are chelated to them may be varied depending on the use envisioned for them.
  • conjugates of the present invention may be used for radiodiagnostic or radiotherapeutic purposes.
  • an antioxidant such as ascorbic acid, is conjugated to a chelating ligand, which form stable complexes with radioactive metals.
  • the chelating ligands that may be used in the practice of the present invention are not particularly limited and are well known to those skilled in the art.
  • Such ligands include, for example, Oxa-PnAO ligands and peptide analogue chelators, such as those with an N 3 S configuration.
  • Radioactive metals include the elements having atomic numbers of 22 to 29, 42, 44 and 58-70.
  • radioactive isotopes include: 99m Tc, 51 Cr, 67 Ga, 68 Ga, m In, 168 Yb, 140 La, 90 Y, 88 Y, 86 Y, 153 Sm, 166 Ho, 165 Dy, 64 Cu, 67 Cu, 97 Ru, 103 Ru, 186 Re, 188 Re, 203 Pb, 211 Bi, 212 Bi, 213 Bi, 214 Bi, 215 Bi, and 177 Lu.
  • Oxa-PnAO ligands or N,N-Me 2 -Gly-Ser-Cys-Gly are preferably used to form conjugates with an antioxidant, such as ascorbic acid.
  • the antioxidants used in the invention are not particularly limited, provided that the antioxidant can be conjugated to a ligand and/or targeting molecule, as described herein.
  • antioxidants which may be used in the present invention include ascorbic acid, ⁇ r ⁇ -aminobenzoic acid (PABA), cysteine, monothioglycerol, and gentisic acid. Of these, ascorbic acid is preferred.
  • the conjugates may further comprise targeting molecules such as, for example, proteins, peptides and antibodies that localize to desired areas of the body.
  • Preferred targeting molecules are peptides or analogues thereof and may include a monomer or multimer of one or more peptides.
  • suitable targeting molecules include gastrin releasing peptide (GRP) agonists, such as those disclosed in U.S. Patent No. 6,200,546, incorporated herein by reference in its entirety.
  • GRP gastrin releasing peptide
  • Other useful targeting molecules include those disclosed in U.S. Patent Nos. 5,662,885; 5,780,006; and 5,976,495, incorporated herein by reference in their entirety, and particularly monomers or multimers of TKPPR or analogues thereof.
  • Analogues of a peptide include molecules that target the peptide's receptor with the same or greater avidity, as well as muteins, retropeptides and retroinversion peptides.
  • these analogues may also contain modifications such as substitutions, deletions and/or additions of one or several amino acids, insofar as these modifications do not alter the biological activity of the peptide in a significantly negative manner.
  • General structures of Oxa-PnAO ligands are detailed in U.S. Patent No.
  • N 3 S radionuclide chelators Structures and preparation of peptide-derived N 3 S radionuclide chelators are discussed in U.S. Patent Nos. 5,662,885; 5,780,006 and 5,976,495, each of which is incorporated herein by reference in its entirety.
  • Particularly preferred N 3 S chelators are N,N-dimethyl-Gly-Ser-Cys-Gly and N,N-dimethyl-Gly-t- butylGly-Cys-Gly.
  • Radiopharmaceutical conjugates (either diagnostic or therapeutic) of the present invention confer the added benefit of introducing an antioxidant (such as ascorbic acid) in close proximity to the oxidizable groups on the radiopharmaceutical (either diagnostic or therapeutic).
  • an antioxidant such as ascorbic acid
  • Such oxidizable groups may include, for example, peptides containing methionine or free thiols. Further, such oxidizable groups may be located on either the ligand or a targeting molecule. This covalent attachment of an antioxidant and the chelator (optionally coupled to a targeting ligand) provides additional stability due to the close proximity of the antioxidant to substituents on the radiopharmaceutical that are susceptible to oxidation induced by the decay of the radionuclide.
  • the ester of 6-hydroxy ascorbic acid retains a number of useful antioxidant properties.
  • the amide bond introduced into 6-hydroxy ascorbic acid in the compounds disclosed herein is expected to have greater serum stability than the ester compounds previously disclosed, and thus, to exhibit antioxidant behavior. Therefore, the ascorbic acid or other antioxidant derivatives of the invention are expected to retain their antioxidant properties when conjugated to the chelator and/or targeting molecules, thereby improving the stability of the conjugates.
  • the antioxidant may be attached to the targeting molecule, which is attached to the chelating ligand.
  • the antioxidant may be attached to the C-terminus of a peptide targeting molecule or via the beta or gamma carboxyl group of an aspartic or glutamic acid in the peptide.
  • the 6-amino ascorbic acid could be attached to the N-terminus of the peptide via a di-carboxylic acid such as succinic acid.
  • the antioxidant may be attached to the chelating ligand as shown herein, or using methods known to those skilled in the art.
  • paramagnetic metals include the elements having atomic numbers of 22 to 29, 42, 44 and 58-70.
  • Examples of such metals are chromium (TIT), manganese (II), iron (II), iron (III), cobalt (LI), nickel (II), copper (II), praseodymium (III), neodymium (III), samarium (III), gadolinium (III), terbium, (LU), dysprosium (111), holmium (Hi), erbium (111) and ytterbium (III). Chromium (III), manganese (II), iron (III) and gadolinium (111) are preferred.
  • conjugates 22a and 22b are prepared, conjugates 22a and 22b. These conjugates have the following structure:
  • DOTA-G-tri- t-butyl ester 4 an intermediate compound in the synthesis of the conjugate 22, was synthesized starting with glycine benzylester hydrochloride (Aldrich), as described in Scheme 1. Chloroacetylchloride (Aldrich) was added to glycine benzylester hydrochloride in the presence of K 2 CO 3 to produce N-(chloroacetyl)-glycine benzyl ester 1. The ester 1 was added to a suspension of DO3A-tri-t-butyl ester hydrochloride 2 (see U.S. Patent No. 5,573,752) in K 2 CO 3 to produce DOTA-G-tri-t-butyl-benzyl ester 3.
  • Relaxivity of a paramagnetic material in the presence of a large protein such as human seram albumin may be used to study the ability of the compounds of the present invention to bind the target protein.
  • a large protein such as human seram albumin
  • the relaxivity of the former will increase because of an increase in its rotational correlation time. This increase in relaxivity may be used not only to measure the extent of binding but also to evaluate the viability of the paramagnetic agent as a blood pool contrast medium.
  • the relaxivity of the conjugates 22a and 22b in water as well as in water containing a known amount (20%, v/v) of a HSA preparation, known as, seronom (Table 1) were studied.
  • the relaxation time of the samples (22a or 22b) in seronom (TlGd-iigandin s eronom) and in water (Tlod-iigand in water) were measured at 38°C using an IBM PC/20 multispec relaxometer.
  • the sample in aqueous seronom was placed in a centrifree micropartition device (Millipore, Beverly, MA). The device was centrifuged at 500xg for 45 min in a fixed angle rotor (Beckman Model J2-21M, JA-20 rotor). The solution (0.5 mL) was taken from below the filter (unbound Gd-ligand) for [Gd] ICP measurement. The [Gd] of the uncentrifuged sample was also measured as a control. The Fraction Bound was calculated by the following equation:
  • Fraction Bound ([Gd-ligand] contro ⁇ - [Gd-ligand] un 0 und)/ [Gd- ligand]controi- Table 1 details the results of the tests.
  • Table 1 shows that the increase in relaxivity in the presence of seronom is 32% and 14% in the case of 22a and 22b, respectively. Based on these results, it is believed that the binding of these conjugates with HSA may not be strong enough for commercial blood pool MRI applications. However, the described conjugates 22a and 22b may be useful as extravascular MRI contrast agents. Moreover, the chemistry described and the conjugates made herein may be used in other applications such as those discussed herein and may be particularly useful where antioxidant properties of ascorbic acid may be required. It is understood that, for radiopharmaceutical or radiotherapy applications, it is convenient to prepare the complexes of the present invention at, or near, the site where they are to be used.
  • the amount administered may be selected based on the desired use, such as to produce a diagnostic image of an organ or other site of a subject or a desired radiotherapeutic effect, by methods known in the art. Exemplary dosages are those employing about 2-200 mCi rhenium, lutetium, or yttrium (for radiotherapy), or about 10-60 mCi technetium (for imaging).
  • Kits of the present invention comprise one or more vials containing the sterile formulation of a predetermined amount of a complexing ligand, an oxidant and optionally other components such as reducing agents, transfer ligands, buffers, lyophilization aids or bulking agents, stabilization aids, solubilization aids and bacteriostats.
  • the inclusion of one or more optional components in the formulation will frequently improve the ease of synthesis of the radiopharmaceutical by the practicing end user, the ease of manufacturing the kit, the shelf-life of the kit, or the stability and shelf-life of the radiopharmaceutical.
  • the improvement achieved by the inclusion of an optional component in the formulation must be weighed against the added complexity of the formulation and added cost to manufacture the kit.
  • the one or more vials that contain all or part of the formulation can independently be in the form of a sterile solution or a lyophilized solid.
  • Buffers useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of the radiopharmaceuticals include but are not limited to phosphate, citrate, sulfosalicylate, and acetate. A more complete list can be found in the United States Pharmacopeia. Lyophilization aids or bulking agents useful in the preparation of diagnostic kits useful for the preparation of radiopharmaceuticals are known in the art and include lactose, sodium chloride, maltose, sucrose, PEG 8000, cyclodextrins, such as hydroxypropyl- ⁇ -cyclodextrin (HP- ⁇ -CD), dextran, Ficoll, and polyvinylpyrrolidine (PVP).
  • Lyophilization aids or bulking agents useful in the preparation of diagnostic kits useful for the preparation of radiopharmaceuticals are known in the art and include lactose, sodium chloride, maltose, sucrose, PEG 8000, cyclodextrins, such as hydroxypropyl-
  • Stabilization aids such as antioxidants, useful in the preparation of radiopharmaceuticals and in diagnostic kits for the preparation of radiopharmaceuticals include but are not limited to ascorbic acid, para- aminobenzoic acid (PABA), cysteine, monothioglycerol, sodium bisulfite, sodium metabisulfite, gentisic acid, and inositol.
  • PABA para- aminobenzoic acid
  • cysteine monothioglycerol
  • sodium bisulfite sodium metabisulfite
  • gentisic acid sodium metabisulfite
  • inositol inositol.
  • conjugates of ascorbic acid are exemplified, the invention includes conjugates of other antioxidants.
  • one or more additional stabilzation aids may be added to formulations of the conjugates of the invention.
  • Solubilization aids useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of the radiopharmaceuticals include but are not limited to ethanol, glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monooloeate, polysorbates, poly(oxyethylene)poly(oxypropylene)poly(oxyethylene) block copolymers
  • Preferred solubilizing aids are polyethylene glycol, and
  • Bacteriostats useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of the radiopharmaceuticals include but are not limited to benzyl alcohol, benzalkonium chloride, chlorbutanol, and methyl, propyl or butyl paraben.
  • a component in a diagnostic kit can also serve more than one function.
  • a reducing agent can also serve as a stabilization aid
  • a buffer can also serve as a transfer ligand
  • a lyophilization aid can also serve as a transfer, ancillary or co- ligand and so forth.
  • the predetermined amounts of each component in the formulation are determined by a variety of considerations familiar to those skilled in the art. These considerations are in some cases specific for that component and in other cases dependent on the amount of another component or the presence and amount of an optional component. In general, the minimal amount of each component is used that will give the desired effect of the formulation.
  • the desired effect of the formulation is that the practicing end user can synthesize the radiopharmaceutical and have a high degree of certainty that the radiopharmaceutical can be safely injected into a patient and will provide diagnostic information about the disease state of that patient.
  • EXAMPLE 1 The synthesis of methyl (3aS,3bRJaS,8aR)-2,2,5,5- tetramethyltefrahydro-8aH-[l,3]dioxolo[4,5]furo[3,2-d][l,3]dioxine-8a- carboxylate 10 is detailed.
  • Example 3A From sulfite 12 and sulfate 13 (Scheme 2) i) Methyl (4aS,5aR,8aS,8bR)-7J-dimethyltetrahydro-5aH-
  • Example 3B From the tosylate 17 (Scheme 3) i) Methyl (3aS,5R,6S,6aR)-6-hydroxy-2,2-dimethyl-5-( ⁇ [(4- methylphenyl)sulfonyl]oxy ⁇ methyl)dihydrofuro[2,3-d][l,3]dioxole-
  • Ci 0 Hi 5 N 3 O 6 C 43.96, H 5.53, N 15.38, O 35.13%.
  • EXAMPLE 6 The synthesis of (3aR,5S,6R,6aS)-6-hydroxy-2,2-dimethyl-5- ⁇ [(N- ⁇ [4,7, 10-tris(2-tert-butoxy-2-oxoethyl)- 1 ,4,1, 10-tet ⁇ aazacyclododecan- 1 - yl]acetyl ⁇ glycyl)amino]methyl ⁇ dihydrofuro[2,3-d][l,3]dioxole-3a(5H)- carboxylic acid 20a is detailed.
  • EXAMPLE 7 The synthesis of 1,4,7, 10-tetraazacyclododecane-l,4J-triacetic acid, 10- [2-[[2-[[(2R)-2-[(2S)-2, 5-dihydro-3,4-dihydroxy-5-oxo-2-furanyl]-2- hy ⁇ roxyethyl]amino]-2-oxoethyl]amino]2-oxoetl yl]- 21a is detailed.
  • TLC Silica gel, R f 0.50, MeOH/CHCl 3 1/20.
  • TLC Silica gel, R f 0.75, MeOH/CHCl 3 1/10.
  • NCH7CH7 CH7CONHCH7CONH. CH7CONHCH7CONH & CH 2 adjacent to cyclohexyl ring); 3.82 (s, 3H, OCH 3 ); 3.95 (m, 2H, CH 2 adjacent to gulonic ring); 4.19, 4.90, 5.12 (m, 3H, CH's on the gulonic ring); 6.32, 6.48, 6.80 (t, 3H, NH's).
  • EXAMPLE 11 The synthesis of 1,4,7, 10-tetraazacyclododecane-l,4J-triacetic acid, 10- [2-[[[4-[[[[(2R)-2-[(2S)-2, 5-dihydro-3,4-dihydroxy-5-oxo-2-furanyl]-2- hydroxyethyl] amino] carbonyl] cyclohexyljmethyl] amino] -2-oxoethyl] amino]2- oxoethyl]- 21b is detailed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des produits radiopharmaceutiques destinés à des applications diagnostiques et thérapeutiques, des conjugués d'antioxydants et de ligands de chélation métallique, des composés intermédiaires, des méthodes de fabrication de ces produits radiopharmaceutiques, des ligands, des composés intermédiaires, ainsi que des kits de préparation des complexes de ces produits radiopharmaceutiques.
EP01987230A 2000-10-31 2001-10-31 Conjugues d'antioxydants et de ligands de chelation metallique Withdrawn EP1406669A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24454700P 2000-10-31 2000-10-31
US244547P 2000-10-31
PCT/US2001/046002 WO2002040060A2 (fr) 2000-10-31 2001-10-31 Conjugues d'antioxydants et de ligands de chelation metallique destines a des applications diagnostiques et therapeutiques

Publications (1)

Publication Number Publication Date
EP1406669A2 true EP1406669A2 (fr) 2004-04-14

Family

ID=22923208

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01987230A Withdrawn EP1406669A2 (fr) 2000-10-31 2001-10-31 Conjugues d'antioxydants et de ligands de chelation metallique

Country Status (5)

Country Link
EP (1) EP1406669A2 (fr)
JP (1) JP2004526671A (fr)
AU (1) AU2002239468A1 (fr)
CA (1) CA2421182A1 (fr)
WO (1) WO2002040060A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305422D0 (en) 2003-03-10 2003-04-16 Univ Open Detection, monitoring and treatment of cancer
EP1466629A1 (fr) * 2003-04-11 2004-10-13 BRACCO IMAGING S.p.A. Produits d'addition entre reactifs pour RNM et substrats contenant des protons èchangeables pour des applications "CEST"
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
EP1940841B9 (fr) * 2005-10-07 2017-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
DE102012208375B4 (de) * 2012-05-18 2015-07-23 Zentralklinik Bad Berka Gmbh Satz und Verfahren zur Herstellung eines Radiopharmakons
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
KR101603699B1 (ko) * 2014-01-10 2016-03-15 경북대학교 산학협력단 Do3a-아미노메틸사이클로헥산 콘쥬게이트를 포함하는 가돌리늄 착물
WO2020007822A1 (fr) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Nanoparticules de bismuth métallique (0), procédé de fabrication et utilisations de celles-ci

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0240060A3 *

Also Published As

Publication number Publication date
CA2421182A1 (fr) 2002-05-23
JP2004526671A (ja) 2004-09-02
WO2002040060A2 (fr) 2002-05-23
AU2002239468A1 (en) 2002-05-27
WO2002040060A3 (fr) 2003-12-31

Similar Documents

Publication Publication Date Title
RU2073005C1 (ru) Хелатное соединение металла
US5650133A (en) Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
JP2831073B2 (ja) 大環状二官能キレート剤、その錯体及びそれらの抗体接合体
CN108368067B (zh) 二聚造影剂
RU2743167C2 (ru) Контрастные агенты
HU222761B1 (hu) Karboxamid-módosított poliamin kelátorok és radioaktív komplexek, valamint konjugátumok
PT90959B (pt) Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos
JP2002515462A (ja) 診断および治療用途に用いるホレート誘導化金属錯体
CN118955616B (zh) 一种靶向结合成纤维细胞活化蛋白化合物及应用
CN108779082B (zh) 造影剂
JP3541951B2 (ja) ジキレート化剤としてのポリアザシクロアルカン
JPH09500115A (ja) イメージング用官能化三脚状配位子類
EP1406669A2 (fr) Conjugues d'antioxydants et de ligands de chelation metallique
CN119866334A (zh) 靶向成纤维细胞活化蛋白的组合物及其使用方法
ES2240517T3 (es) Complejos, que contienen perfluoroalquilo, con radicales de azucares, procedimiento para su preparacion y su utilizacion.
CN104478862B (zh) 适于作为用于对淀粉样沉积物成像的化合物的前体的新的苯并呋喃
CN109963838B (zh) 二聚造影剂
AU2021407769A1 (en) Ligands and their use
US7582280B2 (en) Conjugates of antioxidants with metal chelating ligands for use in diagnostic and therapeutic applications
KR101106433B1 (ko) 암 조직의 타겟팅을 위한 마크로사이클릭 아미노산 계열의 유도체 및 그의 방사성 또는 비방사성 금속 표지화합물
HUT67602A (en) Process for producing bicyclo-polyaza-macrocyclo-carboxylic acid complexes, their conjugates and contrast materials containing them
WO1995028392A1 (fr) Composes chelateurs
KR20230050552A (ko) 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물
Balla Click chemistry mediated cell uptake–towards triggered Auger therapy
KR100306331B1 (ko) 비사이클로폴리아자매크로사이클로카복실산착체,그의결합체,그의제조방법및조영제로서의그의용도

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030526

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061019